Gilead Sciences in charts: HIV, oncology sales climb as revenue from other products falls YY

Related
Occidental outlines $500M in 2025 cost reductions and target...
7 minutes ago
0
Krispy Kreme terminates McDonald’s partnership citing ‘unsus...
7 minutes ago
0
Progyny raises full-year 2025 revenue guidance to $1.27B as ...
8 minutes ago
0
Monster Beverage outlines selective price adjustments and in...
9 minutes ago
0
Hut 8 targets 90% long-term contracted energy capacity and s...
9 minutes ago
0
Star Bulk outlines $104M in vessel sale proceeds and targets...
11 minutes ago
0
Motorola Solutions raises full-year outlook to $11.65B reven...
14 minutes ago
0
Ligand raises 2025 revenue and EPS guidance to $225M and $7 ...
29 minutes ago
0
Gen Digital raises annual revenue guidance to $4.8–$4.9B as ...
29 minutes ago
0
BlackSky outlines $105M–$130M 2025 revenue target as Gen-3 s...
33 minutes ago
0
Horizon Technology Finance outlines $165M capital infusion t...
34 minutes ago
0
EPAM outlines 13–15% revenue growth target for 2025 as CEO t...
41 minutes ago
0
Nu Skin targets $1.48B–$1.55B revenue and $3.05–$3.25 EPS fo...
51 minutes ago
0
Xeris raises 2025 revenue guidance to $280M–$290M following ...
52 minutes ago
0
Akebia outlines access to over 275,000 dialysis patients for...
57 minutes ago
0
Trending
Popular
اعزام اورژانس هرمزگان به مرز شلمچه
4 days ago
3
© FBT Company 2025. All rights are reserved